August 22, 2023
ViGeneron gets EMA approval for Retinitis Pigmentosa related gene therapy
ViGeneron GmbH, a Germany-based gene therapy company, has received from the European Medicines Agency (EMA) an approval for its Clinical Trial Application (CTA) for VG901, a potentially transformative gene therapy to treat CNGA1-associated Retinitis Pigmentosa (RP), an ocular disorder currently lacking approved therapies.